血栓性疾病抗血小板聚集药物研究进展  

Development of antiplatelet agents for thrombotic diseases

作　　者：韩聪凡 冯文化[1] 

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京100050

出　　处：《中国新药杂志》2016年第12期1363-1369,共7页Chinese Journal of New Drugs

摘　　要：血栓性疾病发病率逐年升高,严重威胁人类的生命健康,是当代医学研究的重点和热点之一。抑制血小板聚集是防止血栓形成的主要手段,因此抗血小板聚集药物的研究是预防血栓性疾病的热点。阿司匹林和氯吡格雷是抗血小板聚集的标准治疗方案,但两药联用导致的出血率增加以及阿司匹林和氯吡格雷抵抗使其难以满足临床需要。本文从ADP受体和凝血酶受体拮抗剂和Xa因子抑制剂这3个方面综述了近年来的新型抗血小板药物研究进展。Thrombotic diseases caused by the formation of blood clots inside blood vessels have become a serious threat to human health and antiplatelet therapy is the main method to treat this disease. At present the combined use of aspirin and clopidogrel is the standard antiplatelet regimen. But this combination has shown some shortcomings in clinical applications,making this therapy difficult to meet the clinical needs. Recently the approval of several novel antiplatelet agents is encouraging for patients and provides more treatment options for the clinic.This paper reviewed the development of antiplatelet agents from the following aspects： ADP receptor antagonists,thrombin receptor antagonists,and factor Xa inhibitors.

关 键 词：抗血小板聚集药 P2Y12受体拮抗剂 PAR-1受体拮抗剂 XA因子抑制剂 

分 类 号：R973[医药卫生—药品]